Scientists have identified a protein that appears to put the brakes on the chronic inflammation linked to aging. Older mice ...

Infex Therapeutics announces positive phase IIa study results for RESP-X in NCFB patients colonised with Pseudomonas aeruginosa: Cheshire, UK Saturday, May 23, 2026, 18:00 Hrs [IS ...

ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in ...

AI-mediated discovery has fundamentally changed who shows up to your website and what they expect when they get there.

Coffee may give your blood pressure a temporary jolt, but that doesn’t mean it’s secretly wrecking your heart. Researchers ...

Keir Starmer, Britain's first Labour prime minister in 14 years, is fighting for his political life as mainstream parties ...

AI won't take your job. An AI-native human will. Here's what separates those who thrive from those who get displaced.

A phase 2 trial of Sanofi's experimental therapy for alpha-1 antitrypsin deficiency (AATD) has raised the hope of an ...

Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company advancing next-generation, long-acting bispecific antibodies for immunology and inflammation, today announced ...

Targeted extended circulation LNP incorporating DARPins achieved complete B cell depletion in nonhuman primates through highly specific in vivo CD8+ T cell engineeringRobust study quantifies ...

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide ...